Boehringer vows quick action on manufacturing issues raised by FDA

05/23/2013 | PharmaTimes (U.K.)

Boehringer Ingelheim has announced it will act quickly to settle complaints from the FDA over violations at its headquarters in Germany. The FDA published a warning letter on its website citing the drugmaker's failure to hold a thorough investigation of foreign particles in the active pharmaceutical ingredient of a treatment that was not named. The letter also claimed that Boehringer did not reject treatments that failed to meet accepted specifications or standards and other pertinent quality-control benchmarks.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY